Xeris Biopharma Holdings, Inc.
XERS
$5.48
-$0.25-4.36%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 111.04M | 91.60M | 59.29M | 58.44M | 71.62M |
| Total Receivables | 51.05M | 53.75M | 53.05M | 46.33M | 40.42M |
| Inventory | 68.67M | 67.46M | 67.28M | 52.69M | 48.18M |
| Prepaid Expenses | 9.55M | 11.21M | 5.96M | 6.03M | 7.45M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | -- | -- | -- | -- | -- |
| Total Current Assets | 240.31M | 224.02M | 185.58M | 163.49M | 167.66M |
|
|
|||||
| Total Current Assets | 240.31M | 224.02M | 185.58M | 163.49M | 167.66M |
| Net Property, Plant & Equipment | 27.06M | 27.21M | 27.69M | 27.79M | 28.21M |
| Long-term Investments | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Goodwill | 22.86M | 22.86M | 22.86M | 22.86M | 22.86M |
| Total Other Intangibles | 88.08M | 90.79M | 93.50M | 96.21M | 98.92M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 5.22M | 5.32M | 5.06M | 5.10M | 5.41M |
| Total Assets | 383.53M | 370.19M | 334.69M | 315.45M | 323.06M |
|
|
|||||
| Total Accounts Payable | 3.08M | 6.53M | 9.46M | 6.35M | 2.29M |
| Total Accrued Expenses | 76.41M | 81.61M | 58.14M | 50.78M | 56.80M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 6.23M | 6.19M | 6.16M | 18.08M | 21.18M |
| Total Finance Division Other Current Liabilities | 23.86M | 21.87M | 21.42M | 19.86M | 20.17M |
| Total Other Current Liabilities | 23.86M | 21.87M | 21.42M | 19.86M | 20.17M |
| Total Current Liabilities | 109.57M | 116.20M | 95.17M | 95.07M | 100.44M |
|
|
|||||
| Total Current Liabilities | 109.57M | 116.20M | 95.17M | 95.07M | 100.44M |
| Long-Term Debt | 220.34M | 219.47M | 218.63M | 217.81M | 217.01M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 31.53M | 31.99M | 32.44M | 32.87M | 33.26M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 8.40M | 3.39M | 7.75M | 4.83M | 1.97M |
| Total Liabilities | 369.84M | 371.05M | 353.99M | 350.58M | 352.68M |
|
|
|||||
| Common Stock & APIC | 685.02M | 681.55M | 663.73M | 645.98M | 642.27M |
| Retained Earnings | -671.31M | -682.39M | -683.01M | -681.08M | -671.86M |
| Treasury Stock & Other | -25.00K | -25.00K | -24.00K | -25.00K | -25.00K |
| Total Common Equity | 13.69M | -861.00K | -19.30M | -35.13M | -29.62M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 13.69M | -861.00K | -19.30M | -35.13M | -29.62M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 13.69M | -861.00K | -19.30M | -35.13M | -29.62M |
|
|
|||||